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Cancera b s t r a c t
BCG is a widely used vaccine worldwide for neonates including Pakistan. BCG has more than 90%
coverage through the EPI program which was introduced in 1965 in Pakistan. BCG has limited efﬁcacy
against the transmissible form of pulmonary tuberculosis in high TB endemic countries. However, BCG
vaccination continues in these countries because BCG confers protection against the disseminated form
of TB in children. BCG has also shown some protection against leprosy and certain forms of cancers. One
reason for such nonspeciﬁc protection may be that BCG activates APCs via PAMPS that interacts with TLRs
(2, 4 & 8), which initiate the inﬂammatory cascade thereby recruiting inﬂammatory cells to the site of
infection and providing maturation signals for neutrophils, macrophages and dendritic cells. Such activa-
tion may be crucial for restricting the infection at the initial site. Furthermore, activation of the pro-
inﬂammatory cascade also results in expression of adhesion molecules, co-stimulatory molecules as well
as MHC class II molecule. MHC class II molecules engage CD4+ cells via the TCR receptor while the adhe-
sion and costimulatory molecules bind to their respective receptors on CD4+ T cells for additional high
afﬁnity binding for T cell activation. Although activation of the innate arm may not provide subsequent
memory, activation of T cells may introduce a certain level of memory response and therefore, may form
a rational basis for BCG immunotherapy. This review, therefore, focuses on the immune activation related
to both the innate and adaptive arm of the immune response that has been reported and further explores
the utility of BCG immunotherapy related to non TB conditions.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
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BCG is an attenuated strain isolated from Mycobacterium bovis,
and was ﬁrst identiﬁed by a French scientist Albert Calmette Guer-
in. BCG was ﬁrst used in 1921 as a vaccine in humans. It is a widely
used vaccine to protect against tuberculosis and leprosy [1,2]. The
serial passage of virulent strain of bovine tuberculosis on glycerine
bile potato media reduces its virulence while retaining its antigenic
properties. The efﬁcacy of BCG against pulmonary tuberculosis is
still controversial in several parts of the world with the highest
burden of TB [2,3]. The duration of immunity is somewhere
between 15 and 60 years post immunization in different trials
[4,1]. The variable efﬁcacy of vaccine in different trials has been
attributed to variation in different BCG strains, genetic differences
in different population [5], prior exposure to non tuberculous
mycobacteria [6], and recurrent parasitic infection [7]. However,
the reasons for variable protective immunity still remain unclear.
To address these issues, a large scale trial was initiated in Chingle-
put area of South India in 1968 (15 year follow-up was completed
in 1987) with the assistance of Indian Council of Medical Research.
These results revealed no convincing protection against pulmonary
tuberculosis. Irrespective of the ﬁnding of the Chingleput trial, BCG
vaccination was incorporated in EPI program in 1974 and contin-
ued as part of routine vaccination at birth.
Efﬁcacy of BCG in protection against adult tuberculosis is both
debatable and controversial. A wide range of efﬁcacy (0–80%) has
been reported in case control [8] and cohort studies [2] as well as
in clinical trials [9–11]. The reasons for these variable results are
not clear; however there is consensus that these are true biological
effects and not just due to sampling errors [3]. However, BCG does
provide some extent of protection against TB meningitis and mili-
ary disease. This is evidenced in Chingleput trial (initiated in
1968) where no case of TB meningitis or miliary TB was reported
for over a 14 year period. The protective effect in randomized con-
trolled trials was 86% (95% CI: 65–95) and in case-control studies
was 75% (95% CI: 61–84). The reason of homogenous response is
partly due to younger subjects who were less likely to be exposed
to atypical mycobacteria. Exposure to atypical mycobacteria
presumably obviates protective effect [12]. The role of BCG in infec-
tious diseases was studied thoroughly in both TB and leprosy before
observation of its non-speciﬁc effects in some cancers. Though BCG
was recognized as a vaccine for tuberculosis, widespread BCG cov-
erage has signiﬁcantly declined the cases of leprosy. It was also evi-
dent that BCG vaccinated population in high TB endemic setting
had signiﬁcant impact in declination of leprosy cases [2,13,14].
The efﬁcacy against leprosy ranges between 20 and 80% in con-
trolled trials and observational studies [2,15]. BCG was equally
effective against lepromatous as well as a tuberculoid form of lep-
rosy. Given the efﬁcacy of BCG against leprosy, countries like Brazil,
Cuba and Venezuela recommended the use of BCG for leprosy con-
tacts. A meta-analysis of 26 studies, that included 7 clinical trials
and 19 observational studies (cohort and case control) showed an
overall average protection of 26% (96% CI: 14–37%) against leprosy
[16]. In observational studies, the protective effect was 61% (95% CI:
51–70%) with signiﬁcant heterogeneity (P < 0.00001). The reason
for heterogeneity between studies could be explained by different
population, method of exposure and outcome assessment.
2. Rationale of BCG use as adjuvants
The ﬁrst observation for the use of BCG in enhancement of
immune response was evidenced by use of mycobacteria in prepa-
ration of Freund’s adjuvant in the late 1950s [17]. Complete Fre-
und’s adjuvant (CFA) contains heat killed mycobacteria or BCG
and trehalose 6,6’ dimycolate (TDM) that activates some innate
receptors including TLR2, 4 and 9. CFA stimulates a delayed typehypersensitivity reaction at the site which is skewed towards Th1
immunity. In contrast, incomplete Freund’s adjuvant (IFA) which
lacks mycobacterial component induces Th2 or antibody mediated
immunity [18,19]. This is the ﬁrst observation regarding use of
BCG for activation of immune system. The ﬁndings of CFA induced
arthritis and autoimmune reaction in experimental animals also
provide us a rationale of BCG therapy in non-communicable dis-
eases [20,21] . Historically, it was also shown that parasitic, viral
and bacterial infection resulted in regression of tumors [22]. The
hypothesis of concomitant or cross over immunity due to the pres-
ence of cross reactive antigen (parasite’s egg) also provides an indi-
rect evidence of protection against reinfection in intermediate host
[23,24]. It is a well established fact that parasitic infection induced
Th2 immunity [25] and therefore, a switch from Th1 to Th2 immu-
nity is thought to be involved in tumor regression [26,27]. This host
parasite relationshipwas ﬁrst brought into concept of tumor immu-
nology byDr.WilliamColey in 1898. Coley administered his vaccine
directly into tumor and observed tumor regression. Coley’s toxin or
vaccine comprised of a mixture of killed bacteria, (Serratia marces-
cens and S. pyogenes), whichwas effective against inoperable sarco-
mas. In case of Coley’s vaccine, an infection precedes spontaneous
regression of tumor, supports the idea of non-speciﬁc innate immu-
nity in regression rather than adaptive immune response. This idea
was further translated into BCG adjuvant therapy in melanoma and
bladder cancers. The immune mechanism related to BCG is largely
unknown. In this review, we try to shed some light on non-speciﬁc
immunity conferred by BCG in melanoma and bladder cancers.
2.1 BCG immunotherapy in melanoma cancer
Cutaneous melanoma is the most common skin cancer in
United States with annual adjusted incidence of 22/100,000 popu-
lation in men and 14/100,000 population in women of all races
[28]. The incidence is lower in black and Asian Paciﬁc Islander
(API) compared to whites with predominance of males affected
by this disease [29]. Approximately 15% of primary melanomas
develop into distant metastases; the ﬁve year survival rate for met-
astatic melanoma is still less than 5% despite of advancement in
treatment and diagnosis. Melanoma is one of the cancers that show
regression spontaneously or due to intervention with adjuvant
immunotherapy presumably because of inﬁltration of immune
cells at the tumor site [30,31]. The adjuvant immune therapy with
BCG has also shown promising results for patients after surgical
resection in advanced malignant melanoma [31].
Prior vaccination with BCG or vaccinia in childhood had signiﬁ-
cant effect in case reduction compared to the non-vaccinated group.
A multicenter case control trail of Febrile infection and melanoma
(FEBIM), evaluated risk of melanoma and vaccination status in child
hood for either BCG or vaccinia or both in six European countries
and Israel. This study also addressed the effect of severe infection
and risk of melanoma compared to subjects either vaccinated with
BCG or vaccinia. The odds ratio for individuals not vaccinated for
any of the vaccine were compared to BCG [OR 0.23;(95% CI: 0.05–
0.91)] and vaccinia [OR 0.33;(CI:0.10–1.06)] in persons below
50 years of age, signiﬁes the effect of severe infection on reducing
risk of melanoma [32]. Prior immunization with BCG or vaccinia
vaccine was further evaluated on survival of melanoma patients
during a ﬁve year follow up. A hazard ratio of 0.69 (95% CI: 0.49–
0.98) with BCG compared to 0.52 (95% CI: 0.34–0.79) with vaccinia
vaccine for development of melanoma suggests an immune surveil-
lance mechanism of BCG for melanoma skin cancer [33]. Human
endogenous retroviral genes (HERV–K) encoded envelop protein
is expressed in many cases of melanoma [34] which cause malig-
nant transformation by altering intracellular redox potential [35].
The immune surveillance mechanism of BCG, vaccinia or contact
with other infectious agents was described by the presence of
N. Talat Iqbal, R. Hussain / Trials in Vaccinology 3 (2014) 143–149 145analogs of HERV KMEL epitope by these infectious agents, that gen-
erate cross reactive T cell for elimination of malignant cells [35].
The intra-lesional therapy for melanoma cancer with BCG was
initiated approximately three decades ago, when Morton et al.
reported regression of melanoma using live BCG in 62% of patients.
The result of this and other trials reported serious side effects like
chills, fever and granuloma formation. Results of few successful tri-
als are given in Table 1 [36–42]. Most of these trials showed a posi-
tive response when BCG was mixed with either the Melanoma cell
vaccine (MCV) or autologous tumor cell vaccine. These strategies
resulted in better disease free survival and overall survival. A
newer strategy of ILBCG therapy involves topical treatment of 5%
imiquimod (TLR7 agonist) following BCG injections. The topical
imiquimod treatment up to 5 months resulted in complete regres-
sion in 56% of patients, and 67% remained disease free up to the
last follow-up (range 12–58 months). This treatment modality
was well tolerated in stage III patients, the major limitation was
small sample size of trial [36].
2.2. BCG immunotherapy in bladder cancer
BCG immunotherapy was also described by Morales et al. in
1976. Intravesical BCG is now being used as standard therapy for
non-muscle invasive bladder cancer (NMIBC), which resulted in
70–75% complete response rates in CIS (Carcinoma insitu) [43].
The combination of BCG and MMC in nine clinical trials, showed
no signiﬁcant difference between MMC and BCG in ORs of progres-
sion in a follow-up of 26 months [44], however maintenance dose
with BCG resulted in signiﬁcant superiority over MMC (OR = 0.66;
95% CI: 0.47–0.94; P = 0.02).
The phenomenon of pre-existing immunity to BCG for better
response to therapy requires further investigation in clinical stud-
ies. The effect of prior BCG vaccinationwas also observed in bladder
cancer for improved survival in vaccinated or PPD+ patients treated
with intravesical BCG therapy [45]. This hypothesis of preexisting
immunity to BCG was further tested in orthotropic tumor modelTable 1
Clinical studies on adjuvant BCG therapy and their outcome.
Author Year Stage No. of Patients Treatment
Kidner et al. 2012 III IL BCG + Imquimod




Morton et al. 2007 III n = 1160 BCG + Melanoma cell
vaccine(MCV)
IV n = 496
Haanen et al. 2006 III n = 25 autologus tumor cell
vaccine and BCG
Agarwal et al 2004 I n = 734
III cohort 1 BCG vs observ
Cohort 2 BCG vs addit
dacarbazine
Henz et al. 1996 I no treatment = 22 treatment with two BC
vaccines
BCG RIV = 40
BCG pasteur = 44
Czarnetzki et al. 1993 I BCG RIV = 108 Different BCG prepara
vs no treatment
BCG Pasteur = 109
Follow up only = 110
DFS: Disease free survival; OS:overall survival; CTC: circulating Tumor cell.implanted with MB49 tumor cells in bladder cancer; results of this
study showed thatmice receiving BCG subcutaneously before intra-
vesical therapy showed 100% survival up to 70 days post tumor
challenge compared to 80% survival up to 50 days with no prior
BCG exposure [45]. However, report from Elsaber showed no appar-
ent difference in frequency of IFNc producing CD4+ T cells in
responder vs. non responder to BCG therapy [46], but the presence
of multifunctional IFNc/IL2 positive T cells and higher IFNc+ve cells
in PPD+ve patients represents boosting effect of BCG as observed in
TB patients [47]. Recently, concomitant use of vitamin D with BCG
has been shown to improve invitro toxicity of BCG induced THP-1
cells on BCa cells [48]. It is well known that BCG antigen activates
TLR on macrophages that activates vitamin D signaling pathway
and induces expression of antimicrobial peptide Cathelicidin [49].
Cathelicidin also possess immuno-modulatory effect on immune
cells and act as chemoattractant for neutrophils and a number of
chemokine including IL8 [50]. The use of vitamin D with BCG has
been shown to augment the cytotoxic effect of THP-1 cell on BCa
cells [48]. The instillation of BCG+vitamin D prolonged the survival
up to 70 days in mice compared to BCG alone. Though vitamin D
possess anti-inﬂammatory properties [51,52], it is interesting to
know whether or not vitamin D changes the phenotype of pro-
inﬂammatory M1 macrophages into anti-inﬂammatory M2 pheno-
type during BCG therapy co administered with vitamin D. Further
studies are required to unfold the interaction of BCG and vitamin
D for cancer therapy.
The predominant cell types after BCG instillation in bladder
cancer are neutrophils [53,54], NK cells [55] and T cells [45].
Within these populations, neutrophils are the most important cell
types for BCG mediated local immune response, T cell trafﬁcking
and stimulation of chemokine (IL8 and MIP1a,GRO-a) [56].
3. BCG mediated immune modulation
The generalized mechanism of BCG mediated immune








median follow up 21.9 months pretreatment
DFS (HR 1.64, p = 0.002) OS;HR 1.53, p = 0.028)
Yes [37]
DFS(HR1.91, p = 0.02) OS; (HR 2.57, p = 0.012)
based on 5 yrs survival Yes [38]
42.3% of stage IV
63.4% of stage III
median survival 22.5 months with presence of
TAA speciﬁc T cells vs 4.5 months for absence
of TAA speciﬁc TILS inside melanoma tissue.
(log rank, p = 0.0094)
Yes [39]
5 year survival No [40]
ation cohort 1 (DFS, p = 0.84) (OS, p = 0.40)
ion of cohort 2 (DFS, p = 0.74) (OS, p = 0.81)
G median follow up 6 years Yes [41]
DFS with BCG pasteur (p = 0.02)
tion median follow up 6 years No [42]
Patients survival (p = 0.82)
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these mediators are thought to act in non-speciﬁc manner. The
predominant cytokines stimulated by BCG are IFNc, IL2 and TNFa
secreted by activated CD4+ T cells [57]. These IFNc producing CD4+
T cells possess phenotype of CCR7+ CD62L representing the central
memory T cell population in invitro experiments[57] and in neo-
nates post vaccination at 6 and 27 weeks [58]. A majority of IFNc
producing T cells possess central memory phenotype. However, a
smaller subset of T effector cells is also displayed by BCG. To coun-
ter balance the IFNc secretions, IL10 is secreted by T regulatory
cells (Tregs). BCG activated CD4+CD25+ Tregs act nonspeciﬁcally
against inﬂammation caused by non TB related conditions such
as atherosclerosis [59], type 1 diabetes [60] and asthma [61].
BCG vaccine promotes Tregs cells and cytokines such as TGFb
and IL10 [62]. New strategies to suppress Tregs or anti-inﬂamma-
tory cytokines with BCG vaccine are considered as one of the pos-
sibilities to improve BCG vaccination at birth such as use of anti
IL10 antibodies. BCG vaccination at birth was shown to be well cor-
related with Th1/Th17/ Tregs proﬁling. BCG speciﬁc Tregs attenu-
ate BCG response at vaccination due to inhibition of IFNc [63]
and are therefore considered as one of the reasons of failure of
BCG vaccine. Exposure to environmental mycobacteria before
BCG administration in neonates resulted in increased IL10 or Tregs
cells [63]. This indicates that BCG itself derived Tregs in addition
with other T cell subsets (Fig. 1). This regulation of Tregs by BCG
has implication on counter balancing non-speciﬁc inﬂammation
in other non-communicable diseases such as cancers and diabetes.
3.1. Activation of innate arm
The initial immune response to BCG is dependent on complex
series of events between immune cells andmolecules. The foremost
step is the activation of innate immune system via TLRs through
PAMPS. The cell wall antigens of BCG mainly activate TLR2 and
TLR4 and serves in maturation and activation of macrophages andFig. 1. The battle ﬁeld between BCG and Immune cells: The mechanism of intralesional BC
binding to skin tissue. After the uptake of BCG by receptors, monocytes, neutrophils and N
response. On the basis of cytokine present in the environment, monocytes get differ
macrophages (M1or M2). In the second event, the BCG is internalized through TLRs on ma
stimulatory, molecules such as CD28 and LFA 1 bind to B7 and ICAM-1 for activation of
milieu (C).DCs. The activation of TLRS via these PAMPs activates cascade of
events including activation of adaptor molecule (MYD88) which
results in recruitment of IRAK (IL1 receptor associated kinase) and
TRAF6 (TNF receptor associated factor 6) and MAPK (Mitogen
activated protein kinase), which subsequently activates nuclear
transcription factor (NFkB), and associated genes for section of
pro- inﬂammatory cytokines such as IL1b, IL12 and TNFa [64]. In
case of intralesional injection of BCG, keratinocytes are activated
via TLRs which results in production of pro-inﬂammatory chemo-
kine, antimicrobial peptides, matrix metalloproteinases (MMPs)
and up regulate adhesion molecules such as ICAM-1, VCAM-1, E
selectins and P selectins, that provides a link between innate and
adaptive immune response via NFkB activation pathway [65,66].
Several mycobacterial components including cell wall fractions
(Tx114,mAGP) and DNA up-regulate TRAIL (TNFa ligand superfam-
ily member 10, TNFSF10) and CD62L (L-selectin expressed on B,T
and granulocytes, required for endothelial adhesion) from puriﬁed
neutrophils [67]. Besides this, mycobacterial components such as
Lipoprotein, LPS and CpG oligonucleotide are important Toll
ligands and activate both extracellular and intracellular TLRs
[68,69]. Most commonly activated TLRs by mycobacterial ligands
are TLR2, TLR4 and TLR9. TLR2 is important for TNFa, IL1b and
IL12 secretion from macrophages [70,71]. It also forms heterodi-
mer with TLR6 and recognizes cell wall glycolipids like LAM,
38kd and 19kd lipoprotein. Intracellular TLR9 is activated by
unmethylated CpG motif of bacterial DNA and results in TLR9
dependent dendritic cell activation [69,70]. The glycolipid antigens
present in cell wall of mycobacteria activate CD1 restricted T cells
which was previously reported in leprosy [72].
3.2. Activation of adaptive arm
Internalization of BCG by professional APCs results in activation
of T helper cells. This interaction requires expression of MHC class
II molecule recognized by CD4 T cells via TCR. Engagement of TCRG therapy in melanoma cancer is shown here. BCG binds to ﬁbronectin receptors for
K cells migrate from endothelial to dermal layer (A) for initiation of innate immune
entiated into dermal DCs (DDCs), plasmacytoid DCs (PDCs) or subpopulation of
crophages; BCG antigens are presented on T cell for adaptive immunity (B). T cell co-
T cells. T cells are further differentiated into T cell subsets in response to cytokine
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CD28 to B7-1 on T cells, and up regulation of adhesion molecules
such as lymphocytes function associated antigens- 1 (LFA-1, major
T cell integrin) that binds with intracellular adhesion molecule-1
(ICAM-1) on macrophages [73]. The T cell co stimulation is essen-
tial for T cell activation and anti-tumor responses [74,75]. The key
cytokines released after T cell activation are IL2 and IFNc [76]
(Fig. 1). The local secretion of IFNc is important for expression of
ICAM-1. Expression of ICAM-1 by IFNc also correlates with killing
of tumor cell line [77]. Induction of IFNc by BCG is also important
for IL32 secretion. IL32 is a newly discovered pro-inﬂammatory
cytokine that acts via caspase and IL18 dependent pathway, when
APCs are stimulated speciﬁcally with BCG [78] Differentiation of T
cells into Th17 and Th22 is also dependent on cytokine milieu. IL17
producing Th17 cells differentiate from naïve T cells in the pres-
ence of TGFb, IL6 and IL23. On the other hand, IL22 producing
Th22 cells require IL6 and TNFa [79]. Whether BCG changes local
environment for differentiation of T cells or BCG components drive
this differentiation is still not clear. For tumor cell killing, expres-
sion of FAS ligand and tumor necrosis factor related apoptosis–
inducing ligand (TRAIL) on macrophages and neutrophils are also
involved in apoptosis of tumor cells [53,54]. BCG also generates
human peripheral blood mononuclear cells into special population
of BCG activated killer cells (BAK) [80]. Phenotype of these cells are
CD8+, CD56+ and lymphocyte activated killer cells (LAK) for killing
target cells [80,81]. Th1 cytokines, such as IL2 and IFNc are shown
to activate BAK cells for cytotoxicity [82].
For BCG to impart its role as powerful vaccine or therapeutic
agent, antigen presentation to APCs is the ﬁrst step for an effective
immune response. BCG inhibits inﬂammsome activation via Zn
metalloproteases [83]. The zmp1 deletion mutant of BCG showed
enhanced immunogenicity in terms of antigen presentation, DTH
and increased IFNc production [84]. Like pathogenic strain of
M.tb, if BCG also interferes in phagosome maturation then it pre-
sumably affects the overall efﬁcacy of BCG vaccine in subversion
of host immune system by reducing antigen presentation.4. Conclusion
BCG vaccine, despite its limited efﬁcacy in tuberculosis is still
considered as a useful vaccine for both vaccination and treatment
purpose in melanoma and bladder cancer. The efﬁcacy of BCG as
vaccine or as an immunotherapeutic agent is highly variable in
Pakistan. The available information from invitro and clinical stud-
ies are sparse, and therefore results are inconclusive for its favor-
able use. The result of BCG intravesical therapy in bladder cancer
has equivocal ﬁndings due to high rate of BCG vaccination or expo-
sure to non-tuberculous mycobacteria. One of the complications
associated with intravesical therapy is Gran-P (Granulomatous
Prostatitis) reported in a case report [85]. The other report from
Pakistan (AFIU), showed an overall decrease in recurrence rate
(65% to 12%) and tumor progression (26% to 6%) in 16 patients
who received BCG therapy for 2 weeks after transurethral resection
[86]. In line with these ﬁndings, the use of BCG therapy for breast
cancer treatment has shown promising results in experimental
rat’s model in reversion of chemically induced malignancy [87].
New strategies in BCG immunotherapy may involve use of vita-
min D analogs that might reduce the exacerbated inﬂammatory
process and untoward side effect of BCG in vaccinated population
in high TB endemic setting. Similarly the use of dual toll ligand
(CpG ODN or imiquimod) [88] along BCG intralesional therapy
are promising for treating melanoma cancer. The role of plasmacy-
toid DCs in BCG mediated immune surveillance should be further
investigated using experimental models or clinical studies. Further
studies for non TB use of BCG in type 1 diabetes, arthritis and otherautoimmune conditions are needed to explore the beneﬁts of vac-
cine in non TB related conditions.
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